{"product_id":"biolegend-430501","title":"Biolegend, 430501, ELISA MAX™ Standard Set Human IL-6, 5plates","description":"\u003cp\u003ePlease contact our sales representative for bulk pricing quotations.  ELISA Development Systems Engineered for Sensitive, Precise and Reliable Serum and Plasma Cytokine Quantitation  BioLegend's ELISA Max™ Sets provide all the time-savings, convenience and performance of a high-end, commercial ELISA kit for a fraction of the price! BioLegend's ELISA Max™ Sets, in two appealing formats, address the need for sensitivity, accuracy, dependability, and versatility of an ELISA development system, while providing maximum cost effectiveness, value, and ease of use.  Both the ELISA Max™ Set Standard and ELISA Max™ Set Deluxe are specifically engineered for accurate recovery and measurement of analytes in complex fluids, such as serum and plasma (as well as activated cell cultures) without any interference by confounding serum factors, such as heterophilic antibody or rheumatoid factor.\u003cbr\u003e\n5plates\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nApplication: ELISA\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ishola Jr DA, et al. 2006. Kidney International 2006; doi:10.1038\/sj.ki.5001629PubMed Kim I, et al. 2006. Blood doi:10.1182\/blood-2006-04-014399 Wimmer A, et al. 2006. Blood 108:3722. Inokuchi J, et al. 2009. Carcinogenesis. 30:1028. PubMed Hirari M, et al. 2011. Blood 117:500. PubMed Zhou J, et al. 2015. Cytokine. 71:89. PubMed\u003cbr\u003e\nProduct Citations: Gonzalez-Torres S, et al. 2021. Int J Environ Res Public Health. 19:. PubMed Kirolos SA, et al. 2022. J Leukoc Biol. 112:1399. PubMed Asano T, et al. 2022. J Clin Lipidol. 17:78. PubMed Zhou J, et al. 2015. Cytokine. 71:89. PubMed Chen S, et al. 2021. Exp Ther Med. 22:1049. PubMed Kong B, et al. 2017. J Neuroinflammation. 10.1186\/s12974-017-0961-z. PubMed Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed Zhao M, et al. 2018. Cell Death Dis. 9:582. PubMed Inokuchi J, et al. 2009. Carcinogenesis. 30:1082. PubMed Ban T, et al. 2021. Nat Commun. 12:4379. PubMed Elizondo–Montemayor L, et al. 2019. Mediators Inflamm. 2019:6737318. PubMed Hoang QTM, et al. 2021. Front Med (Lausanne). 8:676058. PubMed Yu Y, et al. 2021. Cell Rep. 37:110126. PubMed Sohail A, et al. 2022. PLoS Pathog. 18:e1010219. PubMed Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed Hirai M, et al. 2011. Blood. 117:500. PubMed Zhang L, et al. 2022. Nat Commun. 13:360. PubMed Stempin CC, et al. 2021. Cancers (Basel). 13:. PubMed Grech D, et al. 2016. J Acupunct Meridian Stud. 9:234-241. PubMed Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed Yang JH, et al. 2021. Molecules. 26:. PubMed He X, et al. 2021. Cell Rep. 36:109392. PubMed Gorby C, et al. 2020. Sci Signal. :13. PubMed Bougarne N, et al. 2019. Front Immunol. 10:1769. PubMed Nieto C, et al. 2018. Front Immunol. 9:31. PubMed\u003cbr\u003e\nStandard Range: 7.8-500 pg\/mL\u003cbr\u003e\nCell Sources: T cells, B cells, macrophages, bone marrow stromal cells, fibroblasts, keratinocytes, mesangium, astrocytes, endothelial cells\u003cbr\u003e\nBiology Area: Immunology, Innate Immunity\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nGene ID: 3569\u003cbr\u003e\nUniProt: View information about IL-6 on UniProt.org\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: ELISA Kit\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864263545001,"sku":"430501","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-430501","provider":"Iright","version":"1.0","type":"link"}